CN102948483B - Blood fat reducing milk powder and preparation method thereof - Google Patents
Blood fat reducing milk powder and preparation method thereof Download PDFInfo
- Publication number
- CN102948483B CN102948483B CN201210508501.1A CN201210508501A CN102948483B CN 102948483 B CN102948483 B CN 102948483B CN 201210508501 A CN201210508501 A CN 201210508501A CN 102948483 B CN102948483 B CN 102948483B
- Authority
- CN
- China
- Prior art keywords
- milk powder
- blood lipid
- reducing blood
- content
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a blood fat reducing milk powder and a preparation method thereof. Taking the total weight of the blood fat reducing milk powder as the reference, the blood fat reducing milk powder comprises 2.2%-5.4% of phytosterol ester, 0.021%-0.068% of docosahexaenoic acid and 0.011%-0.054% of eicosapentaenoic acid. The preparation method of the blood fat reducing milk powder comprises the following steps of dosing, filtering, homogenization, concentration, atomization, dry-blending and packaging, wherein the phytosterol ester is mixed with other raw materials in the dosing step, and the dosing step is carried at the temperature of 40-50 DEG C; the homogenization step is carried out at the temperature of 37-60 DEG C; and the docosahexaenoic acid and eicosapentaenoic acid are mixed with other raw materials in the dry-blending step. The milk powder mainly comprises phytosterol ester, DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) as active compositions, and the three active compositions are enabled to play synergic effect in the milk powder, so that the effect of reducing blood fat is played.
Description
Technical field
The present invention relates to a kind of reducing blood lipid milk powder and preparation method thereof, belong to dairy products field.
Background technology
Along with improving constantly of people's living standard, people's life style also changes occurring, and crowd's spectrum of disease changes, to the morbidity of hypertension, Chronic Non-Communicable Diseases that high fat of blood is relevant with dead increasing.The feature of China's modern way of life is exactly fast pace, harmonic motion, abundant in content and form is single, therefore because bad life style causes a series of bad disease, serious threat health of people, in addition due to many-sided factors such as the intense and stimulative increase of mental emotion, dietetic nutrition unreasonable structure, the pollution of environment, the people of Smoking And Drinking increase, cause the causality disease incidences such as cardiovascular disease, cerebrovascular disease, diabetes, malignant tumour to increase, the major reason that become premature death, disables.And in the risk factors of various chronic diseases, high fat of blood is one of key factor wherein.High fat of blood can cause hypertension, bring out gall stone, and pancreatitis increases the weight of hepatitis, causes male sexual disfunction, the disease such as senile dementia, and current research prompting high fat of blood may be relevant with the morbidity of cancer.
At present, the patient of hyperlipemia is very general, and according to " Chinese residents nutrition and investigation of health conditions " result demonstration of State Council's issue in 2004, China dyslipidemia crowd has reached 1.6 hundred million.It also produces the impact can not be ignored on kidney, peripheral circulation, pancreas, pruritus, immune system, disease in the blood system.Therefore, for prevention and control high fat of blood, be more and more subject to people's attention.
The strict difinition of high fat of blood should be blood fat disorder or dyslipidemia, the concentration level that refers to blood in human body in fat eliminating matter has exceeded normal range (NR), comprises that serum total cholesterol (Tc) level raises, serum levels of triglyceride (TG) level raises, serum High Density Lipoprotein Cholesterol (HDL-C) level lowers.Divide two kinds of primary and Secondary cases.Hyperlipemia is a chronic process, conventionally without any symptom, but there do not have symptom to be not equal to blood fat to be not high, slight high fat of blood is conventionally without any uncomfortable sensation, be not easy to cause people's attention, most people is found when health check-up, but its harm to human body health can not be ignored.
The harm of hyperlipidemia be concealment, gradually, carrying out property and general, when Hyperlipemia, can make cholesterol and so on electrodeposition substance in vascular wall, form gradually atherosclerotic plaque.Research datas show in a large number, and hyperlipidemia is the important risk factor of the diseases such as headstroke, coronary heart disease, myocardial infarction.The Scandinavia Simvastatin existence test routine coronary heart disease of person 4444 and moderate hyperlipidemia patient, accept Simvastatin Treatment and observe 5 or 4 years. and coronary heart disease case fatality rate and total case fatality rate decline respectively 42% and 30%.When Blood Cholesterol increases, easily form arteriosclerosis plaque, these plaque deposits cause cerebral infarction when the cerebrovascular, and cerebral infarction is multiple is born in people above middle age, and majority has hypertension, diabetes, heart disease or hyperlipemia.Many studies have shown that, adjusts fat treatment can obviously lower incidence and the disability rate of headstroke for a long time, and meanwhile, hyperlipidemia is also to cause atherosclerotic, coronary heart disease, cerebrovas-cularaccident, finally causes the principal element of glycosuria death.In recent years, along with the change of people's dietary structure and life style, the incidence of disease of hyperlipemia rises year by year, and it has become the main factor of bringing out fatty liver.In recent years, global epidemiology investigation shows, the illness rate of fatty liver is 17%-33%.Therefore, clinician more and more payes attention to the treatment of high fat of blood.
Phytosterol (phytosterol or plant sterol) is a kind of active component being extensively present in plant, at seed, vegetable oil, fruit, vegetables equal size, will be many, what occurring in nature was the most common, content is maximum be cupreol (β-sitosterol), campesterol (campesterol), stigmasterol (stigmasterol), β-sitostamol (β-sitostanol), campestanol (campestanol) etc.Phytosterol (take stigmasterol as example) has the chemical constitution as closely similar in cholesterol (cholesterine) with animality sterol (as shown in following structural formula):
Due to the similar cholesterol of phytosterol chemical constitution, therefore, in human body digestion process, phytosterol can replace cholesterol in human body intestinal canal chylomicron Zhong position, reduces the absorption of cholesterol in human body intestinal canal, increases the excretion of cholesterol.Research shows, human body can not synthesizing phytosterol, can only from food, absorb.But the absorptivity of phytosterol is very low in meals, average out to 5% left and right.Phytosterol is not the essential composition as human body, and the food ration of human body can be different and different with people's eating habit.It is reported, Japanese intake is per capita that 300mg/d-450mg/d ，Er Northern European countries is lower, is 200mg/d-300mg/d.Weststrate (a kind of new type functional food-phytosterin ester, Chinese oil, the 26th the 3rd phase of volume of calendar year 2001) etc. the various cholesterol effects in blood of falling that are rich in phytosterol margarine have been reported, confirm to absorb every day the tablespread that is added with 8%-10% phytosterol (spreads) of average normal amount (two Europeans are approximately 209), can make serum total cholesterol and LDL-C decline 8%-13%, this is equivalent to absorb the phytosterol between 1.6g-2.0g every day.Phytosterol also has effect for reducing fat to normal adult, Sierksma (character of phytosterol, function and application, foreign medical science hygiene fascicle, the 28th the 5th phase of volume of calendar year 2001) in the double blind control research that Deng Dui76Ming health adult (44 years old mean age) carries out, find, compare with control group, take sojasterol 0.8s/a and can significantly reduce TC and LDL in blood after 3 weeks, but can not cause in blood that other liposoluble vitamin is as the decline of Hu trailing plants b element level.
Yet, although phytosterol and phytostanol have good reduction serum cholesterol effect, but its solubility in fat and water is limited, so free phytosterol and phytostanol are not the optimal selection for diet batching as cholesterol-lowering agent.Experiment shows, phytosterin ester has than the lowering cholesterol effect of the more excellent liposoluble of phytosterol and Geng Jia.Phytosterin ester is the class natural constituents in vegetable oil, and its lowering cholesterol effect is just known very early, and phytosterin ester is a kind of fatty acid ester blends that phytosterol and aliphatic acid form by chemical reaction.Phytosterin ester can change into phytosterol and aliphatic acid in human body, so its physiological function comprises the physiological function that phytosterol and aliphatic acid two parts have.It is as follows that phytosterin ester reduces cholesterol mechanism of action:
(1) because phytosterol has stronger hydrophobicity than cholesterol, so phytosterol can replace cholesterol and enters in mixed micelle (mixed micelles).This metalepsis declines the cholesterol level in protomere, thereby reduces the absorption of cholesterol.The reduction of cholesterol absorption rate likely stimulates its synthetic increasing, in a research, compare with control group meals, phytosterin ester and plant stanol ester can make respectively the synthetic increase by 53% and 38% of cholesterol, but synthetic increase can not full remuneration phytosterin ester and the degree that reduces of the caused cholesterol absorption of plant stanol ester, and therefore the total cholesterol level in circulation reduces.
(2) phytosterin ester can slow down the esterification rate of cholesterol in enterocyte.Because the sterol after esterification is easy to enter in chylomicron, nonesterified sterol is chylomicron more difficult to get access, so phytosterin ester can reduce the total amount of cholesterol in chylomicron.
Essential fatty acid (essential fatty acids, EFA) refers to that human body maintains that body eubolism is indispensable and self can not synthesize or aggregate velocity cannot meet body requirement slowly, the aliphatic acid that must provide by food.Essential fatty acid mainly comprises two kinds: the alpha-linolenic acid (18: 3) of a kind of ω of being-3 series, a kind of is the linoleic acid (18: 2) of ω-6 series, alpha-linolenic acid in human body (18: 3) can synthesize eicosapentaenoic acid (EPA) and DHA (DHA), research shows, eicosapentaenoic acid (EPA) and DHA (DHA) have different physiological roles, the edible EPA that is rich in, the fish oil of DHA, not only can effectively reduce the content of blood in human body in clearing gallbladder sterol and low-density lipoprotein, reduce the generation of angiocardiopathy, and there is anticoagulation, anti-inflammatory and the effect such as anticancer.The physiological function of DHA, EPA is as shown in table 1 below.
Table 1
Note: √ is the effective a of zoopery and has been used for the treatment of artery sclerosis b approval and is used for the treatment of hyperlipemia
Progressively raising along with people's living standard, people's dietary structure has also occurred to change significantly, the requirement of food has been turned to " high nutrition; have health to be worth " by " only can wrap up in abdomen ", people more and more focus on taking in the nutrition arrangement of meals, and milk powder has the pith that abundant nutrition has become people health care.Therefore the milk powder of, developing a kind of not only nutrition but also tool health care becomes one of this area problem demanding prompt solution.
Summary of the invention
For solving the problems of the technologies described above, the object of the present invention is to provide a kind of reducing blood lipid milk powder and preparation method thereof, this milk powder mainly comprises phytosterin ester and DHA, EPA as active component, and three brings into play synergy in milk powder, plays the effect that reduces blood fat.Reducing blood lipid milk powder of the present invention has solved independent use phytosterin ester or the required dosage of DHA, EPA is large, financial burden weight, and take in a short time the problem of poor effect.
For reaching above-mentioned purpose, the invention provides a kind of reducing blood lipid milk powder, the gross weight of this milk powder of take is benchmark, and its raw material forms and comprises phytosterin ester 2.2%-5.4%, DHA 0.021%-0.068% and eicosapentaenoic acid 0.011%-0.054%.
According to the specific embodiment of the present invention, preferably, the gross weight of this milk powder of take is benchmark, and the raw material of described reducing blood lipid milk powder forms and comprises phytosterin ester 4.2%, DHA 0.043% and eicosapentaenoic acid 0.026%.
According to the specific embodiment of the present invention, preferably, described reducing blood lipid milk powder is prepared by following steps: batching, filtration, homogeneous, concentrate, spray, be dry mixed and pack; Wherein, described phytosterin ester is to mix with other raw materials at described batching step, and described batching step carries out at 40-50 ℃; Described homogenizing step carries out at 37-60 ℃; Described DHA and eicosapentaenoic acid are to mix with other raw materials in the described step that is dry mixed.
In the milk powder of above-mentioned reduction blood fat, preferably, described phytosterin ester is refinement from corn oil, extraction, concentrated and purified, and the grease that linolenic sunflower oil carries out esterification, purifying gained is rich in utilization.The buying standard (if no special instructions, the percentage composition in following table 2 is weight percentage) as shown in table 2 below of described phytosterin ester.
Table 2
In the milk powder of above-mentioned reduction blood fat, preferably, described DHA, eicosapentaenoic acid are contained in a fish oil powder, the gross weight of described fish oil powder of take is benchmark, content >=13.8% of DHA in described fish oil powder, content >=8.0% of eicosapentaenoic acid.The buying standard (if no special instructions, the percentage composition in following table 3 is weight percentage) as shown in table 3 below of described fish oil powder.
Table 3
According to the specific embodiment of the present invention, preferably, the gross weight of this milk powder of take is benchmark, and the raw material of described reducing blood lipid milk powder forms one or more the combination also comprising in raw milk, skimmed milk power, desalted whey powder and PURE WHEY etc., its content >=70%.At this, it should be noted that, in reducing blood lipid milk powder of the present invention, the content of arbitrary raw material all refers to that the dry of this raw material accounts for the content in described milk powder.
According to the specific embodiment of the present invention, preferably, the gross weight of this milk powder of take is benchmark, and the raw material of described reducing blood lipid milk powder forms and also comprises: the combination of one or more in the Bifidobacterium that the lactase that the oligoisomaltose that the maltodextrin that the white granulated sugar that the soybean oil that content is 1-3.5%, content are 5-12.5%, content are 5-20%, content are 1-3%, content are 0.08-0.64% and content are 0.01-0.05% etc.
According to the specific embodiment of the present invention, preferably, the raw material of described reducing blood lipid milk powder forms and also comprises vitamin, the reducing blood lipid milk powder of take described in every 100 grams is benchmark, and described vitamin comprises one or more the combination in following material: vitamin A 300 μ gRE-900 μ gRE, vitamin D 6.3 μ g-12.5 μ g, vitamin E 10mg α-TE-18mg α-TE, Cobastab
20.5mg-1.2mg, Cobastab
60.8mg-1.6mg and vitamin C 30-100mg etc.
According to the specific embodiment of the present invention, preferably, the raw material of described reducing blood lipid milk powder forms and also comprises trace element, the reducing blood lipid milk powder of take described in every 100 grams is benchmark, and described trace element comprises one or more the combination in following material: calcium 700mg-1300mg, iron 6.0mg-10.0mg and zinc 3.0mg-6.0mg etc.
The present invention also provides a kind of preparation method of reducing blood lipid milk powder, and it comprises the following steps: batching, filtration, homogeneous, concentrate, spray, be dry mixed and pack; Wherein, described phytosterol is to mix with other raw materials at described batching step, and described batching step carries out at 40-50 ℃; Described homogenizing step carries out at 37-60 ℃; Described DHA and eicosapentaenoic acid are to mix with other raw materials in the described step that is dry mixed.In preparation method of the present invention, described filtration, concentrated, spraying and packing can be the conventional steps that milk powder is prepared in this area.
According to the specific embodiment of the present invention, preferably, the preparation method of described reducing blood lipid milk powder comprises the following steps:
Batching: at 40-50 ℃, phytosterol is mixed (wherein with other raw materials, described other raw materials can comprise: the combination of one or more in raw milk, skimmed milk power, desalted whey powder and PURE WHEY etc., the combination of one or more in soybean oil, white granulated sugar, maltodextrin, oligoisomaltose and lactase etc., multivitamin, and various trace elements), obtain mixed liquor;
Filter: by the Impurity removal in above-mentioned mixed liquor, the mixed liquor after being filtered;
Homogeneous: under 37-60 ℃, 5-15MPa homogenization pressure, the mixed liquor after above-mentioned filtration is carried out to homogeneous, obtain the mixed liquor after homogeneous;
Concentrated sterilizing: the mixed liquor after above-mentioned homogeneous is carried out to the concentrated sterilizing of material, and sterilization temperature is 85-93 ℃, obtains the mixed liquor after concentrated sterilizing;
Spraying is dry: the mixed liquor after above-mentioned concentrated sterilizing is sprayed dry, dried compound powder obtains spraying;
Be dry mixed: at room temperature, DHA and eicosapentaenoic acid are mixed with the dried compound powder of above-mentioned spraying (while containing Bifidobacterium in the raw material of described reducing blood lipid milk powder forms, also together mix with the dried compound powder of described spraying being dry mixed the same DHA of step, EPA), the milk powder after being dry mixed;
Packing: after the milk powder after above-mentioned being dry mixed is packed, obtain described reducing blood lipid milk powder.
According to the specific embodiment of the present invention, more preferably, the preparation method of described reducing blood lipid milk powder comprises the following steps:
Milk collection: raw milk was unified to pump weighs, Ru Nai storehouse after the assay was approved;
Clean breast: the raw milk in Jiang Nai storehouse, through duplex strainer, filters impurity wherein;
Preheating: the raw milk that filters impurity is preheated to 40-50 ℃, squeezes into material-compound tank, prepare batching;
Batching: at 40-50 ℃, the phytosterol having melted is in advance mixed (wherein with other raw materials, described other raw materials can comprise: the combination of one or more in raw milk, skimmed milk power, desalted whey powder and PURE WHEY etc., the combination of one or more in soybean oil, white granulated sugar, maltodextrin, oligoisomaltose and lactase etc., multivitamin, and various trace elements; At this, it should be noted that, when milk powder of the present invention does not adopt raw milk to be raw material, the step of so above-mentioned milk collection, clean breast and preheating can be omitted), obtain mixed liquor;
Filter: above-mentioned mixed liquor is passed through to wherein Impurity removal of duplex strainer, the mixed liquor after being filtered;
Homogeneous: 37-60 ℃, successively under one-level homogenization pressure 5-10MPa, double-stage homogenization pressure 10-15MPa, the mixed liquor after above-mentioned filtration is carried out to homogeneous, obtain the mixed liquor after homogeneous;
Concentrated sterilizing: the mixed liquor after above-mentioned homogeneous, through triple effect evaporator, is carried out to the concentrated sterilizing of material, and wherein an effect evaporating temperature is 56-69 ℃, two effect evaporating temperatures are 55-65 ℃, triple effect evaporation temperature is 40-52 ℃, and sterilization temperature is 85-93 ℃, obtains the mixed liquor after concentrated sterilizing;
Spraying is dry: the mixed liquor after above-mentioned concentrated sterilizing is sprayed dry, EAT is 170-200 ℃, and temperature of outgoing air is 82-92 ℃, and dried compound powder obtains spraying;
Be dry mixed: at room temperature, DHA and eicosapentaenoic acid are mixed with the dried compound powder of above-mentioned spraying (while containing Bifidobacterium in the raw material of described reducing blood lipid milk powder forms, also together mix with the dried compound powder of described spraying being dry mixed the same DHA of step, EPA), the milk powder after being dry mixed;
Packing: the milk powder after above-mentioned being dry mixed, by packing after pipeline feeding, sealing, coding, vanning, packing, is obtained to described reducing blood lipid milk powder.
In the preparation method of reducing blood lipid milk powder of the present invention, under 40-50 ℃ of condition, prepare burden, be different from the step that prior art is prepared burden at normal temperatures, batch temperature of the present invention can make phytosterin ester better dissolve, do not solidify, not only contribute to bring into play the blood fat reducing function of phytosterin ester, and be beneficial to carrying out smoothly of production; In addition, after batching step, without feed liquid is carried out to cold treatment, but remain at 37-60 ℃, carry out homogeneous, the problem that can avoid phytosterin ester to solidify at normal temperatures, further better dissolves phytosterin ester, better brings into play its effect; In addition, adopt the mode being dry mixed that DHA, EPA are mixed with dried other raw materials of spraying, this is because DHA, EPA are thermal sensitivity active nutrient component, and the mode that dry method is added can reduce conventional wet method and add the nutritive loss causing.
Reducing blood lipid milk powder of the present invention is usingd phytosterin ester and DHA, EPA as active component, by special preparation technology, makes three in milk powder, bring into play synergy, plays the effect that reduces blood fat.Reducing blood lipid milk powder of the present invention has solved independent use phytosterin ester or the required dosage of DHA, EPA is large, financial burden weight, and take in a short time the problem of poor effect.
The specific embodiment
Embodiment
The present embodiment provides a kind of reduction blood fat milk powder, and it comprises that following raw material forms (unit is kg, and wherein, the dry matter content of raw milk is about 11.8wt%, and the moisture in other raw materials is negligible):
Wherein, in described fish oil powder, the content of DHA is that the content of 14.3wt%, EPA is 8.6wt%; Described B B-complex comprises (in every 100g reducing blood lipid milk powder): vitamin A 512 μ gRE, vitamin D 8.1 μ g, vitamin C 75mg, vitamin e1 3.5mg α-TE, Cobastab
61.1mg; Described composite trace element comprises (in every 100g reducing blood lipid milk powder): calcium 1050mg, iron 8.0mg, zinc 4.5mg.
The present embodiment provides a kind of preparation method of above-mentioned reduction blood fat milk powder, and it comprises the following steps:
Milk collection: raw milk was unified to pump weighs, Ru Nai storehouse after the assay was approved;
Clean breast: the raw milk in Jiang Nai storehouse, through duplex strainer, filters impurity wherein;
Preheating: the raw milk that filters impurity is preheated to 50 ℃, squeezes into material-compound tank, prepare batching;
Batching: at 50 ℃, add skimmed milk power, desalted whey powder, PURE WHEY, the phytosterin ester having melted in advance, oligoisomaltose, maltodextrin, B B-complex and composite trace element in the raw milk of preheating, obtain mixed liquor;
Filter: above-mentioned mixed liquor is passed through to duplex strainer by Impurity removal wherein, the mixed liquor after being filtered;
Homogeneous: 37 ℃, successively under one-level homogenization pressure 9MPa, double-stage homogenization pressure 12MPa, the mixed liquor after above-mentioned filtration is carried out to homogeneous, obtain the mixed liquor after homogeneous;
Concentrated sterilizing: the mixed liquor after above-mentioned homogeneous, through triple effect evaporator, is carried out to the concentrated sterilizing of material, and wherein an effect evaporating temperature is 63 ℃, two effect evaporating temperatures are 60 ℃, triple effect evaporation temperature is 48 ℃, and sterilization temperature is 90 ℃, obtains the mixed liquor after concentrated sterilizing;
Spraying is dry: the mixed liquor after above-mentioned concentrated sterilizing is sprayed dry, EAT is 196 ℃, and temperature of outgoing air is 88 ℃, and dried compound powder obtains spraying;
Be dry mixed: at room temperature, fish oil powder and Bifidobacterium are mixed to the milk powder after being dry mixed with the dried compound powder of above-mentioned spraying;
Packing: the milk powder after above-mentioned being dry mixed, by packing after pipeline feeding, sealing, coding, vanning, packing, is obtained to described reducing blood lipid milk powder.
Comparative example
This comparative example provides a kind of reduction blood fat milk powder, and the raw material that its raw material forms embodiment forms identical.
This comparative example also provides the preparation method of above-mentioned reduction blood fat milk powder, and it comprises the following steps:
Milk collection: raw milk was unified to pump weighs, Ru Nai storehouse after the assay was approved;
Clean breast: the raw milk in Jiang Nai storehouse, through duplex strainer, filters impurity wherein;
Batching: (25 ℃) at normal temperatures, in the above-mentioned raw milk that filters impurity, add skimmed milk power, desalted whey powder, PURE WHEY, the phytosterin ester having melted in advance, oligoisomaltose, maltodextrin, B B-complex and composite trace element, obtain mixed liquor;
Filter: above-mentioned mixed liquor is passed through to duplex strainer by Impurity removal wherein, the mixed liquor after being filtered;
Homogeneous: (25 ℃), priority are carried out homogeneous to the mixed liquor after above-mentioned filtration under one-level homogenization pressure 9MPa, double-stage homogenization pressure 12MPa at normal temperatures, obtain the mixed liquor after homogeneous;
Concentrated sterilizing: the mixed liquor after above-mentioned homogeneous, through triple effect evaporator, is carried out to the concentrated sterilizing of material, and wherein an effect evaporating temperature is 63 ℃, two effect evaporating temperatures are 60 ℃, triple effect evaporation temperature is 48 ℃, and sterilization temperature is 90 ℃, obtains the mixed liquor after concentrated sterilizing;
Spraying is dry: the mixed liquor after above-mentioned concentrated sterilizing is sprayed dry, EAT is 196 ℃, and temperature of outgoing air is 88 ℃, and dried compound powder obtains spraying;
Be dry mixed: (25 ℃) at normal temperatures, fish oil powder and Bifidobacterium are mixed to the milk powder after being dry mixed with the dried compound powder of above-mentioned spraying;
Packing: the milk powder after above-mentioned being dry mixed, by packing after pipeline feeding, sealing, coding, vanning, packing, is obtained to described reducing blood lipid milk powder.
Phytosterin ester content detection
By the reducing blood lipid milk powder censorship finished product phytosterol ester content of embodiment and comparative example gained.Testing result is: in the milk powder of embodiment, phytosterol ester content is 3788mg/100g, and in the milk powder of comparative example, phytosterol ester content is 3046mg/100g.Hence one can see that, and the preparation technology of embodiment can make phytosterin ester better dissolve, and does not solidify, and makes in product the content of phytosterin ester higher, not only contributes to bring into play the blood fat reducing function of phytosterin ester, and be beneficial to carrying out smoothly of production.
Lipid-lowering effect contrast experiment
This contrast experiment's experiment crowd meets following 3 requirements: 1, the age is the male sex of 18-65 one full year of life and women totally 120 people; 2, the crowd who meets simple dyslipidemia, as serum total cholesterol (TC) >=5.2mmol/L or serum levels of triglyceride (TG) >=1.65mmol/L; 3, non-hyperlipemic patients of being in hospital, and experimental session keeps life and eating habit on ordinary days.
This contrast experiment's experimental technique comprises the following steps:
1, according to random-blind method principle, and consider the impact of age, sex, dietary factor, experiment crowd is divided into experimental group and control group, experiment A organizes 30 people, experiment B organizes 30 people, and experiment C organizes 30 people, control group 30 people, and carry out statistical analysis according to four groups of experiment crowds' blood lipid level, require edible front four groups of experiment crowds' blood lipid level there was no significant difference.
2,, in above four groups of experiment crowds, A organizes and eats milk powder A, the 25g that only adds phytosterin ester every day; B organizes and eats milk powder B, the 25g that only adds fish oil powder (being rich in DHA and EPA) every day; C group eats milk powder C, the 25g of interpolation phytosterin ester and fish oil powder (being rich in DHA and EPA) every day; D organizes to eat and does not add milk powder D, the 25g that phytosterin ester does not add fish oil powder (being rich in DHA and EPA) yet every day.Wherein, the preparation method of milk powder A, B, C, D and raw material form with embodiment basic identical, difference is that the addition of phytosterin ester, DHA and EPA is different, and in described milk powder A, B, C, D, the content of phytosterin ester, DHA and EPA is as shown in table 4 below.
3, test after 60 days, get the experiment crowd's of experimental group A, B, C and control group D limosis vein blood, measure blood lipid level, comprise serum total cholesterol (TC), triglycerides (TG), HDL-C (HDL-C), LDL-C (LDL-C), blood fat overall target (TG/HDL-C) situation of change is analyzed as follows shown in table 5.
Table 4
| Milk powder | A | B | C | D |
| Phytosterin ester content g/25g milk powder | 1.35 | 0 | 1.05 | 0 |
| DHA content mg/25g milk powder | 0 | 12 | 9.5 | 0 |
| EPA content mg/25g milk powder | 0 | 6.8 | 5 | 0 |
Table 5
Result by table 5 can draw to draw a conclusion: check is learned in the variation of blood fat overall target (TG/HDL-C) by statistics, difference has statistical significance, proof phytosterin ester and DHA, the preparation-obtained reducing blood lipid milk powder of EPA compatibility, obtained excellent synergy at reduction lipid aspects.
Claims (15)
1. a reducing blood lipid milk powder, the gross weight of this milk powder of take is benchmark, its raw material forms and comprises phytosterin ester 2.2%-5.4%, DHA 0.021%-0.068% and eicosapentaenoic acid 0.011%-0.054%;
This milk powder is prepared by following steps: batching, filtration, homogeneous, concentrate, spray, be dry mixed and pack; Wherein, described phytosterin ester is to mix with other raw materials at described batching step, and described batching step carries out at 40-50 ℃; Described homogenizing step carries out at 37-60 ℃; Described DHA and eicosapentaenoic acid are to mix with other raw materials in the described step that is dry mixed.
2. reducing blood lipid milk powder as claimed in claim 1, the gross weight of this milk powder of take is benchmark, its raw material forms and comprises phytosterin ester 4.2%, DHA 0.043% and eicosapentaenoic acid 0.026%.
3. reducing blood lipid milk powder as claimed in claim 1 or 2, wherein, described phytosterin ester is refinement from corn oil, extraction, concentrated and purified, and utilizes and be rich in the grease that linolenic sunflower oil carries out esterification, purifying gained.
4. reducing blood lipid milk powder as claimed in claim 1 or 2, wherein, described DHA, eicosapentaenoic acid are contained in a fish oil powder, the gross weight of described fish oil powder of take is benchmark, content >=13.8% of DHA in described fish oil powder, content >=8.0% of eicosapentaenoic acid.
5. reducing blood lipid milk powder as claimed in claim 1 or 2, the gross weight of this milk powder of take is benchmark, its raw material forms and also comprises: the combination of one or more in raw milk, skimmed milk power, desalted whey powder and PURE WHEY, its content >=70%.
6. reducing blood lipid milk powder as claimed in claim 1 or 2, the gross weight of this milk powder of take is benchmark, and its raw material forms and also comprises: the combination of one or more in the active Bifidobacterium that the lactase that the oligoisomaltose that the maltodextrin that the white granulated sugar that the soybean oil that content is 1-3.5%, content are 5-12.5%, content are 5-20%, content are 1-3%, content are 0.08-0.64% and content are 0.01-0.05%.
7. reducing blood lipid milk powder as claimed in claim 5, the gross weight of this milk powder of take is benchmark, and its raw material forms and also comprises: the combination of one or more in the active Bifidobacterium that the lactase that the oligoisomaltose that the maltodextrin that the white granulated sugar that the soybean oil that content is 1-3.5%, content are 5-12.5%, content are 5-20%, content are 1-3%, content are 0.08-0.64% and content are 0.01-0.05%.
8. reducing blood lipid milk powder as claimed in claim 1 or 2, its raw material forms and also comprises vitamin, the reducing blood lipid milk powder of take described in every 100 grams is benchmark, and described vitamin comprises one or more the combination in following material: 3-Hydroxyretinol 00 μ gRE-900 μ gRE, vitamin D 6.3 μ g-12.5 μ g, vitamin e1 0mg α-TE-18mg α-TE, Cobastab
20.5mg-1.2mg, Cobastab
60.8mg-1.6mg and vitamin C 30-100mg.
9. reducing blood lipid milk powder as claimed in claim 5, its raw material forms and also comprises vitamin, the reducing blood lipid milk powder of take described in every 100 grams is benchmark, and described vitamin comprises one or more the combination in following material: 3-Hydroxyretinol 00 μ gRE-900 μ gRE, vitamin D 6.3 μ g-12.5 μ g, vitamin e1 0mg α-TE-18mg α-TE, Cobastab
20.5mg-1.2mg, Cobastab
60.8mg-1.6mg and vitamin C 30-100mg.
10. reducing blood lipid milk powder as claimed in claim 6, its raw material forms and also comprises vitamin, the reducing blood lipid milk powder of take described in every 100 grams is benchmark, and described vitamin comprises one or more the combination in following material: 3-Hydroxyretinol 00 μ gRE-900 μ gRE, vitamin D 6.3 μ g-12.5 μ g, vitamin e1 0mg α-TE-18mg α-TE, Cobastab
20.5mg-1.2mg, Cobastab
60.8mg-1.6mg and vitamin C 30-100mg.
11. reducing blood lipid milk powder as claimed in claim 1 or 2, its raw material forms and also comprises trace element, the reducing blood lipid milk powder of take described in every 100 grams is benchmark, and described trace element comprises one or more the combination in following material: calcium 700mg-1300mg, iron 6.0mg-10.0mg and zinc 3.0mg-6.0mg.
12. reducing blood lipid milk powder as claimed in claim 5, its raw material forms and also comprises trace element, the reducing blood lipid milk powder of take described in every 100 grams is benchmark, and described trace element comprises one or more the combination in following material: calcium 700mg-1300mg, iron 6.0mg-10.0mg and zinc 3.0mg-6.0mg.
13. reducing blood lipid milk powder as claimed in claim 6, its raw material forms and also comprises trace element, the reducing blood lipid milk powder of take described in every 100 grams is benchmark, and described trace element comprises one or more the combination in following material: calcium 700mg-1300mg, iron 6.0mg-10.0mg and zinc 3.0mg-6.0mg.
14. reducing blood lipid milk powder as claimed in claim 8, its raw material forms and also comprises trace element, the reducing blood lipid milk powder of take described in every 100 grams is benchmark, and described trace element comprises one or more the combination in following material: calcium 700mg-1300mg, iron 6.0mg-10.0mg and zinc 3.0mg-6.0mg.
The preparation method of the reducing blood lipid milk powder described in 15. claim 1-14 any one, it comprises the following steps: batching, filtration, homogeneous, concentrate, spray, be dry mixed and pack; Wherein, described phytosterol is to mix with other raw materials at described batching step, and described batching step carries out at 40-50 ℃; Described homogenizing step carries out at 37-60 ℃; Described DHA and eicosapentaenoic acid are to mix with other raw materials in the described step that is dry mixed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210508501.1A CN102948483B (en) | 2012-12-03 | 2012-12-03 | Blood fat reducing milk powder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210508501.1A CN102948483B (en) | 2012-12-03 | 2012-12-03 | Blood fat reducing milk powder and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102948483A CN102948483A (en) | 2013-03-06 |
| CN102948483B true CN102948483B (en) | 2014-01-15 |
Family
ID=47758310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210508501.1A Active CN102948483B (en) | 2012-12-03 | 2012-12-03 | Blood fat reducing milk powder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102948483B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160165914A1 (en) * | 2013-05-20 | 2016-06-16 | Kao Corporation | Fat composition |
| CN104413147A (en) * | 2013-09-11 | 2015-03-18 | 中粮营养健康研究院有限公司 | Grease composition for formula milk powder as well as preparation method and application of grease composition |
| CN106387091A (en) * | 2016-09-09 | 2017-02-15 | 上海应用技术大学 | Phytosterin health-care nutrient powder having efficacy of reducing blood lipid and preparation method |
| CN106578078A (en) * | 2016-12-07 | 2017-04-26 | 南京苏新智慧社区服务有限公司 | Efficient-absorption oligopeptide formula goat milk powder and preparation method thereof |
| CN107771946A (en) * | 2017-10-28 | 2018-03-09 | 卜球 | A kind of formula milk and its production method for contributing to middle-aged and old cardiovascular and cerebrovascular health |
| CN108552320A (en) * | 2018-01-18 | 2018-09-21 | 青岛博智汇力生物科技有限公司 | A kind of chitosan oligosaccharide milk powder beneficial to middle-aged and the old's cardiovascular health |
| CN113545397A (en) * | 2020-04-23 | 2021-10-26 | 黑龙江唯贝美乳业有限公司 | Preparation process and processing method of milk powder of blood fat reducing milk powder |
| CN111937966A (en) * | 2020-08-27 | 2020-11-17 | 内蒙古伊利实业集团股份有限公司 | Formula milk powder capable of reducing blood fat and preparation method thereof |
| CN115486482A (en) * | 2021-06-23 | 2022-12-20 | 临夏州燎原乳业有限公司 | Yak formula milk powder beneficial to cardiovascular health |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305383C (en) * | 2003-11-03 | 2007-03-21 | 东北农业大学 | Active bifidobacteria contained milk powder and its preparation method |
| CN101258875B (en) * | 2008-04-11 | 2010-10-13 | 内蒙古蒙牛乳业（集团）股份有限公司 | Yoghourt useful for lowering blood fat and preparation |
| CN102499290B (en) * | 2011-12-27 | 2013-04-10 | 内蒙古伊利实业集团股份有限公司 | Nutrient milk powder with selenium-enriched lentinus edodes and method for producing nutrient milk powder with selenium-enriched lentinus edodes |
| CN102630754A (en) * | 2012-04-18 | 2012-08-15 | 内蒙古蒙牛乳业（集团）股份有限公司 | Compound liquid dairy product with function of assisting in reducing blood fat and preparation method thereof |
-
2012
- 2012-12-03 CN CN201210508501.1A patent/CN102948483B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102948483A (en) | 2013-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102948483B (en) | Blood fat reducing milk powder and preparation method thereof | |
| CN107771946A (en) | A kind of formula milk and its production method for contributing to middle-aged and old cardiovascular and cerebrovascular health | |
| CN102228241A (en) | Health-care food capable of tonifying brain, enhancing intelligence and enhancing memory and preparation method thereof | |
| WO2011077800A1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
| CN107467497A (en) | A kind of five cereals food therapeutic composition with anti-adiposity health care function and preparation method thereof | |
| CN102159227A (en) | Pharmaceutical composition for purifing vein and preparation method thereof | |
| CN107441217B (en) | Oral emulsion rich in alpha-linolenic acid and preparation method thereof | |
| CN101766274B (en) | Antioxidant functional food composition containing bamboo-leaves flavones | |
| KR20100109697A (en) | Functional composition with the effects of improving hyperlipidemia and reducing body weight | |
| CN102511711B (en) | Healthcare food capsule and preparation method for same | |
| CN108851037A (en) | A kind of preparation method and its usage of nephrotic syndrome wholefood | |
| CN108420890A (en) | A kind of composition and preparation method thereof with effect for reducing blood fat | |
| CN105707568A (en) | Alpha-linolenic acid soft capsule with function of auxiliarily lowering blood lipids and preparation method thereof | |
| CN106135898A (en) | A kind of alimentation composition assisting blood fat reducing and preparation method | |
| CN109316565A (en) | A kind of blood-fat reducing composition and its preparation method and application | |
| CN103735603A (en) | Compound lipid-decreasing soft capsule and preparation method thereof | |
| CN107692196A (en) | It is a kind of that there are health products for removing vivotoxin function and preparation method thereof | |
| CN102742829A (en) | Dietetic therapy product for regulating blood fat and preparation method thereof | |
| KR102317197B1 (en) | Health functional food composition using musk rat musk having anti-obesity activity and preparation thereof | |
| CN103478632B (en) | Fruit and vegetable health tablets and method for preparing same | |
| CN102526374B (en) | Hypolipidemic preparation | |
| CN107307401A (en) | A kind of application of composition of integration of drinking and medicinal herbs in lowering blood-fat and reducing weight functional food is prepared | |
| CN104432325A (en) | Pumpkin juice with hpyerglycemic function and preparation method of pumpkin juice | |
| CN104547909B (en) | A kind of Chinese medicine composition of reducing blood lipid and preparation method and application | |
| CN109091523A (en) | Composition containing Golden flower |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130306 Assignee: Durbat Yili Dairy Co.,Ltd. Assignor: Inner Mongolia Yili Industrial Group Co.,Ltd. Contract record no.: X2020980007327 Denomination of invention: A kind of hypolipidemic milk powder and its preparation method Granted publication date: 20140115 License type: Common License Record date: 20201029 |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130306 Assignee: Heilongjiang Yili Dairy Co.,Ltd. Assignor: Inner Mongolia Yili Industrial Group Co.,Ltd. Contract record no.: X2020980007546 Denomination of invention: A kind of hypolipidemic milk powder and its preparation method Granted publication date: 20140115 License type: Common License Record date: 20201105 |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130306 Assignee: Inner Mongolia Jinze Yili Dairy Co.,Ltd. Assignor: INNER MONGOLIA YILI INDUSTRIAL GROUP Co.,Ltd. Contract record no.: X2023990000112 Denomination of invention: A hypolipidemic milk powder and its preparation method Granted publication date: 20140115 License type: Common License Record date: 20230112 |